Company Profiles

driven by the PitchBook Platform

Acumen Pharmaceuticals

Description

Developer of therapeutics and diagnostics designed to treat Alzheimer's disease and other memory-related disorders. The company's therapeutics and diagnostics develops ACU-193, the lead antibody within the Acumen ADDL-Select program which is fully humanized, IgG2 monoclonal antibody that selectively binds soluble Aβ oligomers and potently blocks their deleterious actions, enabling patients to recover faster from degenerative disorders which results from the aging of brain.

1996

Founded

PRIVATE

Status

11-50

Employees

Series A

Latest Deal Type

$20M

Latest Deal Amount

$24.3M

Total Amount Raised

Description

Developer of therapeutics and diagnostics designed to treat Alzheimer's disease and other memory-related disorders. The company's therapeutics and diagnostics develops ACU-193, the lead antibody within the Acumen ADDL-Select program which is fully humanized, IgG2 monoclonal antibody that selectively binds soluble Aβ oligomers and potently blocks their deleterious actions, enabling patients to recover faster from degenerative disorders which results from the aging of brain.

Website:

www.acumenpharm.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

4435 North First Street Suite 360 Livermore, CA 94551United States +1 (925) 368-8508
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Acumen Pharmaceuticals's full profile, request a free trial.

Acumen Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Acumen Pharmaceuticals Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Acumen Pharmaceuticals Investors (7)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Biotechnology Value Fund PartnersPE/BuyoutMinority000 0000000 0000
GDBA InvestmentsVenture CapitalMinority000 0000000 0000
Glynn Capital ManagementVenture CapitalMinority000 0000000 0000
Individual InvestorAngel (individual)Minority000 0000000 0000
NeuroVentures CapitalVenture CapitalMinority000 0000000 0000
Biotechnology Value Fund Partners PE/Buyout
GDBA Investments Venture Capital
Glynn Capital Management Venture Capital
Individual Investor Angel (individual)
NeuroVentures Capital Venture Capital

Acumen Pharmaceuticals Executive Team (2)

NameTitleBoard
Seat
Contact
Info
William Goure Ph.DChief Operating Officer
Daniel O'ConnellChief Executive Officer, Board Member & President
William Goure Ph.D Chief Operating Officer
Daniel O'Connell Chief Executive Officer, Board Member & President

Acumen Pharmaceuticals Board Members (4)

NameRepresentingRoleSinceContact
Info
Franz Hefti Ph.DAcumen PharmaceuticalsBoard Member000 0000
Grant Krafft Ph.DSelfCo-Founder, Chief Scientific Adviser and Chairman of the Board of Directors000 0000
Jeffrey Ives Ph.DSelfBoard Member000 0000
Mark LampertBiotechnology Value Fund PartnersPresident & Founder000 0000
Franz Hefti Ph.D Board Member Acumen Pharmaceuticals
Grant Krafft Ph.D Co-Founder, Chief Scientific Adviser and Chairman of the Board of Directors Self
Jeffrey Ives Ph.D Board Member Self
Mark Lampert President & Founder Biotechnology Value Fund Partners
Request full access to PitchBook